Relatlimab Anti-LAG-3 Antibody
by Dr. C.H. Weaver M.D. 3/2021
Results from the RELATIVITY-047 clinical trial evaluating relatlimab, an anti-LAG-3 antibody, and Opdivo (nivolumab) suggest that combination immunotherapy may represent an attractive new treatment for advanced melanoma. (1)
Opdivo is a precision cancer immunotherapy that belongs to a class of medicines called “checkpoint inhibitors.” Checkpoint inhibitors help to restore the body’s t cells in fighting cancer by releasing checkpoints that cancer uses to shut down the immune system. PD-1 and PD-L1 are proteins that inhibit certain types of immune responses and allow cancer cells to evade detection and attack by certain immune cells in the body. A checkpoint inhibitor can block the PD-1 and PD-L1 pathway and enhance the ability of the immune system to fight cancer. By blocking the binding of the PD-L1 ligand these drugs restore an immune cells’ ability to recognize and fight the lung cancer cells. Opdivo works by blocking PD-1 and is already approved for the treatment of melanoma because it prolongs survival and delays cancer recurrence. (2,3,4) Immune checkpoint inhibitors have transformed melanoma treatment and improved survival rates for patients with advanced melanoma.
The lymphocyte-activation gene 3 (LAG-3) is a cell-surface molecule expressed on the immune systems effector T cells and regulatory T cells (Tregs) and functions to control T cell response, activation and growth. LAG-3 regulates an inhibitory immune checkpoint pathway that limits the activity of T cells, leading to an impaired ability to attack cancer cells. In the chronic presence of diseases like cancer, T cells exhibit progressive exhaustion that is characterized by the upregulation of inhibitory immune checkpoints such as PD-1 and LAG-3. Relatlimab is a LAG-3–blocking antibody that binds to LAG-3 on T cells, restoring the function of exhausted T cells. Studies suggest that blocking the LAG-3 pathway may restore T cell effector function and potentially promote an anti-cancer cell response. While LAG-3 and PD-1 are distinct immune checkpoint pathways, they may work together to improve effector T cell function.
About The RELATIVITY-047 Clinical Trial
RELATIVITY-047 is a Phase 2/3 clinical trial evaluating Opdivo with or without relatlimab in patients with previously untreated metastatic or unresectable melanoma. A total of 714 patients were treated with either a fixed-dose combination of relatlimab 160 mg and Opdivo 480 mg or Opdivo 480 mg alone by intravenous infusion every four weeks until disease recurrence, unacceptable toxicity or withdrawal of consent. The manufacturer of Opdivo and relatlimab has recently stated that the combination delays melanoma recurrence better than treatment with Opdivo alone and data is being submitted to the U.S Food and Drug Administration.
Stay Current - Connect With Other Melanoma Patients
- Join The CancerConnect Community: Connect with others and receive regular updates
- Sign up for the Melanoma Newsletter Here
Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma, Meets Primary Endpoint of Progression-Free Survival
Robert C, Long GV, Brady B, et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. New England Journal of Medicine [early online publication]. November 16, 2014.
Topalian SL, Sznol M, McDermott DF, et al. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. Journal of Clinical Oncology [early online publication]. March 3, 2014. doi: 10.1200/JCO.2013.53.0105.
Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase 3 Trial. Bristol-Myers Squibb website. Available here. Accessed November 17, 2014.